89,990 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company acquired a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 89,990 shares of the company’s stock, valued at approximately $1,126,000. The Manufacturers Life Insurance Company owned about 0.10% of Olema Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its position in Olema Pharmaceuticals by 9,476.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after purchasing an additional 1,232 shares during the last quarter. ProShare Advisors LLC increased its position in shares of Olema Pharmaceuticals by 13.8% during the 4th quarter. ProShare Advisors LLC now owns 14,367 shares of the company’s stock valued at $359,000 after purchasing an additional 1,740 shares during the last quarter. Deutsche Bank AG lifted its stake in shares of Olema Pharmaceuticals by 3.2% in the 4th quarter. Deutsche Bank AG now owns 63,067 shares of the company’s stock worth $1,577,000 after purchasing an additional 1,975 shares during the period. Bank of America Corp DE lifted its stake in shares of Olema Pharmaceuticals by 0.4% in the 3rd quarter. Bank of America Corp DE now owns 802,304 shares of the company’s stock worth $7,855,000 after purchasing an additional 2,802 shares during the period. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in shares of Olema Pharmaceuticals in the fourth quarter worth approximately $88,000. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Stock Performance

OLMA opened at $10.75 on Friday. The company has a 50 day simple moving average of $11.42 and a two-hundred day simple moving average of $13.92. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.86 and a quick ratio of 8.86. The firm has a market cap of $940.62 million, a P/E ratio of -5.07 and a beta of 1.98. Olema Pharmaceuticals, Inc. has a 1-year low of $6.35 and a 1-year high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.06). Equities analysts forecast that Olema Pharmaceuticals, Inc. will post -2.43 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Cyrus Harmon sold 12,500 shares of Olema Pharmaceuticals stock in a transaction that occurred on Thursday, July 23rd. The stock was sold at an average price of $11.58, for a total transaction of $144,750.00. Following the sale, the director owned 715,270 shares of the company’s stock, valued at approximately $8,282,826.60. This trade represents a 1.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 12.56% of the company’s stock.

Analysts Set New Price Targets

OLMA has been the subject of several recent research reports. JPMorgan Chase & Co. cut their target price on shares of Olema Pharmaceuticals from $52.00 to $46.00 and set an “overweight” rating for the company in a research report on Thursday, August 13th. Wall Street Zen cut shares of Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 25th. Guggenheim cut their price objective on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Citigroup reduced their price objective on Olema Pharmaceuticals to $59.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Finally, Weiss Ratings cut Olema Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.40.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.